NATIONAL CENTER FOR TRANSLATIONAL MEDICINE · NATIONAL MEDICAL CENTER FOR HEMATOLOGY

Ruijin Hospital, SJTU School of Medicine

Established in 1907 as Sainte Marie Hospital, Ruijin Hospital of Shanghai Jiao Tong University School of Medicine is one of China’s most celebrated centennial public tertiary academic medical complexes. Formally designated as the National Medical Center for Hematologic Diseases and home to the National Center for Translational Medicine, Ruijin represents global leadership in leukemia targeted differentiation, CAR-T cellular immunotherapy, and robotic cancer surgery.

Built upon the pioneering legacy of Lasker Award laureate Academician Wang Zhenyi and Academician Chen Zhu, Ruijin’s Shanghai Institute of Hematology manages the highest volume of commercial and clinical-trial CAR-T cell infusions in Asia, achieving remarkable complete remission rates in refractory lymphomas, multiple myeloma, and acute lymphoblastic leukemia.

Ruijin Hospital National Center for Hematologic Diseases
Downtown Huangpu Academic Campus Located at 197 Ruijin 2nd Rd, Huangpu District, Downtown Shanghai, with dedicated VIP inpatient towers and translational cleanrooms.
Est. 1907
Centennial Heritage
Historic public tertiary academic hospital
3,000+
Inpatient Beds
Comprehensive clinical & surgical complex
120,000+
Annual Surgeries
High-volume surgical & robotic throughput
#1 in Asia
CAR-T Cell Volume
National Center for Hematologic Diseases

FOUR CLINICAL EXCELLENCE PILLARS

Core Hematology & Surgical Capabilities

Ruijin Hospital integrates world-renowned hematologic oncology research with cutting-edge robotic minimally invasive surgery across complex abdominal and thoracic malignancies.

CAR-T & Cellular Therapy

Comprehensive commercial and investigational CAR-T programs for relapsed/refractory lymphoma, myeloma, and leukemia.

✓ Accredited Clinical Excellence Pillar

Hematologic Malignancies

Pioneering targeted differentiation protocols (ATRA + Arsenic) and high-volume allogeneic stem cell transplantation.

✓ Accredited Clinical Excellence Pillar

Robotic Pancreatic Surgery

Asia’s leading robotic pancreaticoduodenectomy (Whipple) center with superior vascular reconstruction and lymphadenectomy.

✓ Accredited Clinical Excellence Pillar

Translational Medicine Hub

National Center for Translational Medicine offering immediate access to molecular genomic testing and novel clinical trials.

✓ Accredited Clinical Excellence Pillar

WORLD-RENOWNED HEMATOLOGY & SURGICAL CHIEFS

Academic Faculty & Department Leadership

Steered by members of the Chinese Academy of Sciences and Chinese Academy of Engineering.

Academician Wang Zhenyi Faculty

Academician Wang Zhenyi Faculty

Shanghai Institute of Hematology Senior Leadership

Lasker Award winner and pioneer of all-trans retinoic acid (ATRA) for acute promyelocytic leukemia, transforming a fatal malignancy into a 95%+ curable condition.

Focus: Targeted differentiation therapy, leukemia genomics, translational medicine, Lasker Award laureate faculty.
Request Case Review with This Specialist →
Prof. Mi Jianqing, MD, PhD

Prof. Mi Jianqing, MD, PhD

Director of Clinical Hematology · Chief of Cellular Immunotherapy

National leader in clinical CAR-T cell immunotherapy and autologous/allogeneic stem cell transplantation for advanced lymphoma and multiple myeloma.

Focus: CAR-T cell clinical trials, refractory DLBCL, BCMA-directed cellular therapy, stem cell transplantation.
View Full Academician / Specialist Profile →

CASE INTAKE & SPECIALIST TRIAGE

Initiate Your Case Review with Ruijin Hospital

Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential Ruijin Hospital clinical pathways in China and assist you in gathering the specific medical records needed for expert hospital review.

    PATIENT INQUIRIES

    Frequently Asked Questions About Ruijin Hospital

    Key clinical, logistical, and technical facts regarding international admissions, surgical evaluations, advanced technology access, and personalized care coordination at Ruijin Hospital.

    Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), or multiple myeloma who have failed at least two prior lines of therapy.

    From T-cell apheresis to final cell product delivery typically requires 2 to 3 weeks. Patients usually remain hospitalized for approximately 2 to 3 weeks post-infusion for close monitoring and recovery.

    Ruijin’s robotic surgery center performs the highest volume of robotic Whipple procedures in Asia, offering magnified 3D visualization, superior tremor filtration, and reduced blood loss, enabling faster return to oncologic chemotherapy.

    Yes. Ruijin’s National Center for Translational Medicine regularly enrolls eligible overseas patients in cutting-edge bispecific antibody and next-generation CAR-T cellular trials under formal ethical clearance.

    MODERN CLINICAL INFRASTRUCTURE

    Strategic Multi-Campus Setup & International Transit

    Modern clinical hubs designed for seamless aeromedical transport, multidisciplinary conferences, and dedicated international inpatient care.

    Main Academic Campus

    Ruijin Historic Downtown Campus

    197 Ruijin 2nd Road, Huangpu District, Shanghai

    The central academic hospital housing the National Center for Translational Medicine, Institute of Hematology, and VIP towers.

    Northern Medical Campus

    Ruijin Northern Campus (Jiading)

    999 Xiwang Road, Jiading District, Shanghai

    Modern medical center featuring specialized oncology wards, comprehensive imaging infrastructure, and radiation pavilions.

    Ruijin Hospital, SJTU School of Medicine